VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) today announced the first volunteer patient has been enrolled and administered Multikine* (Leukocyte Interleukin, Injection) in a Institutional Review Board approved Phase I Clinical Trial evaluating peri-anal wart immunotherapy in HIV/HPV co-infected men and women at the Naval Medical Center San Diego (NMCSD). The purpose of this dose escalation study is to evaluate the safety and impact of Multikine as a treatment of Human Papilloma Virus associated peri-anal warts and assess the effect on anal intraepithelial dysplasia (AIN) in HIV/HPV co-infected men and women.
The study is being conducted through a Cooperative Research and Development Agreement (CRADA) between CEL-SCI Corporation and Naval Medical Center San Diego. By entering into this CRADA, NMCSD does not directly or indirectly endorse any product or service provided, or to be provided, by CEL-SCI, its successors, assignees, or licensees. CEL-SCI is contributing doses of the investigational drug Multikine and will have the right to exclusively license a new technology developed from the collaboration.
Help employers find you! Check out all the jobs and post your resume.
The study is being conducted through a Cooperative Research and Development Agreement (CRADA) between CEL-SCI Corporation and Naval Medical Center San Diego. By entering into this CRADA, NMCSD does not directly or indirectly endorse any product or service provided, or to be provided, by CEL-SCI, its successors, assignees, or licensees. CEL-SCI is contributing doses of the investigational drug Multikine and will have the right to exclusively license a new technology developed from the collaboration.
Help employers find you! Check out all the jobs and post your resume.
